Antibody responses to bovine parainfluenza virus type 3 (PIV3) vaccination and human PIV3 infection in young infants

Min Shi Lee, David P. Greenberg, Sylvia H. Yeh, Ram Yogev, Keith S. Reisinger, Joel I. Ward, Mark M. Blatter, Iksung Cho, Sandra J. Holmes, Julie M. Cordova, Marilyn J. August, Wendy Chen, Harshvardhan B. Mehta, Kathleen L. Coelingh, Paul M. Mendelman

Research output: Contribution to journalArticlepeer-review

29 Scopus citations

Abstract

A phase 2 clinical trial was conducted to evaluate the antibody responses to bovine parainfluenza virus type 3 (bPIV3) vaccination in young infants. Three groups were tested as follows: placebo (n = 66) and 105 (n = 64) or 106 (n = 62) TCID50 of bPIV3. The vaccine or placebo was administered intranasally at ages 2, 4, 6, and 12-15 months, and serum specimens were collected at ages 2, 6, 7, 12-15, and 13-16 months. Serum hemagglutination inhibition (HI) and IgA antibody titers against bPIV3 and human PIV3 (hPIV3) were measured. The results indicate that antibody responses to bPIV3 vaccination are more likely to be detected by the bPIV3 IgA and HI assays than by the hPIV3 IgA and HI assays, that bPIV3-induced antibody response can be differentiated from hPIV3-induced antibody response most reliably by comparing bPIV3 and hPIV3 HI titers, and that bPIV3 vaccine prevents vaccine recipients from developing antibody profiles of hPIV3 primary infection.

Original languageEnglish (US)
Pages (from-to)909-913
Number of pages5
JournalJournal of Infectious Diseases
Volume184
Issue number7
DOIs
StatePublished - Oct 1 2001

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Antibody responses to bovine parainfluenza virus type 3 (PIV3) vaccination and human PIV3 infection in young infants'. Together they form a unique fingerprint.

Cite this